{"product_id":"pe-22-28-10mg-vial","title":"PE-22-28 10mg vial","description":"\u003cp data-start=\"104\" data-end=\"433\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"104\" data-end=\"433\"\u003e\u003cstrong data-start=\"104\" data-end=\"116\"\u003ePE-22-28\u003c\/strong\u003e is a \u003cstrong data-start=\"122\" data-end=\"138\"\u003eheptapeptide\u003c\/strong\u003e with the sequence \u003cstrong data-start=\"157\" data-end=\"198\"\u003eGVSWGLR (Gly–Val–Ser–Trp–Gly–Leu–Arg)\u003c\/strong\u003e. It is widely described as the \u003cstrong data-start=\"230\" data-end=\"258\"\u003esmallest active fragment\u003c\/strong\u003e derived from the endogenous peptide \u003cstrong data-start=\"295\" data-end=\"305\"\u003espadin\u003c\/strong\u003e, retaining potent antagonism of the \u003cstrong data-start=\"342\" data-end=\"394\"\u003eTREK-1 (KCNK2) two-pore domain potassium channel\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"435\" data-end=\"734\"\u003e\u003cstrong data-start=\"435\" data-end=\"459\"\u003eNomenclature origin:\u003c\/strong\u003e “PE(22-28)” refers to a peptide fragment numbering used in the parent propeptide context described in patents\/literature; the peptide is associated with \u003cstrong data-start=\"613\" data-end=\"672\"\u003esortilin\/NTSR3 propeptide → spadin → PE-22-28 fragments\u003c\/strong\u003e in the discovery chain. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"736\" data-end=\"739\"\u003e\n\u003ch3 data-start=\"741\" data-end=\"782\"\u003e2) Target biology: why TREK-1 matters\u003c\/h3\u003e\n\u003cp data-start=\"783\" data-end=\"1123\"\u003e\u003cstrong data-start=\"783\" data-end=\"801\"\u003eTREK-1 (KCNK2)\u003c\/strong\u003e is a background\/leak K⁺ channel that helps set \u003cstrong data-start=\"849\" data-end=\"879\"\u003eresting membrane potential\u003c\/strong\u003e and dampens excitability. In many neuron types, \u003cstrong data-start=\"928\" data-end=\"980\"\u003einhibiting TREK-1 tends to increase excitability\u003c\/strong\u003e and can shift network activity in ways that have been explored for \u003cstrong data-start=\"1048\" data-end=\"1079\"\u003eantidepressant-like effects\u003c\/strong\u003e, neuroplasticity, and post-injury recovery.\u003c\/p\u003e\n\u003cp data-start=\"1125\" data-end=\"1374\"\u003ePE-22-28’s importance is that it is a \u003cstrong data-start=\"1163\" data-end=\"1196\"\u003ehigh-potency TREK-1 inhibitor\u003c\/strong\u003e reported at \u003cstrong data-start=\"1209\" data-end=\"1242\"\u003esub-nanomolar IC₅₀ (~0.12 nM)\u003c\/strong\u003e in vendor-compiled pharmacology summaries (which typically trace back to primary literature). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1376\" data-end=\"1379\"\u003e\n\u003ch2 data-start=\"1381\" data-end=\"1416\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-start=\"1418\" data-end=\"1459\"\u003e3.1 Receptor\/channel pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"1460\" data-end=\"1775\"\u003e\n\u003cli data-start=\"1460\" data-end=\"1576\"\u003e\n\u003cp data-start=\"1462\" data-end=\"1576\"\u003e\u003cstrong data-start=\"1462\" data-end=\"1481\"\u003ePrimary target:\u003c\/strong\u003e \u003cstrong data-start=\"1482\" data-end=\"1500\"\u003eTREK-1 (KCNK2)\u003c\/strong\u003e inhibition (functional antagonism). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1577\" data-end=\"1775\"\u003e\n\u003cp data-start=\"1579\" data-end=\"1775\"\u003e\u003cstrong data-start=\"1579\" data-end=\"1637\"\u003eImmediate electrophysiologic consequence (conceptual):\u003c\/strong\u003e reduced K⁺ leak conductance → \u003cstrong data-start=\"1668\" data-end=\"1704\"\u003emembrane depolarization tendency\u003c\/strong\u003e → \u003cstrong data-start=\"1707\" data-end=\"1742\"\u003egreater neuronal responsiveness\u003c\/strong\u003e (cell-type and state dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"1777\" data-end=\"1825\"\u003e3.2 Downstream neurobiology (hypothesis map)\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"1826\" data-end=\"2715\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"1826\" data-end=\"1883\"\u003e\n\u003ctr data-start=\"1826\" data-end=\"1883\"\u003e\n\u003cth data-start=\"1826\" data-end=\"1835\" data-col-size=\"sm\"\u003eDomain\u003c\/th\u003e\n\u003cth data-start=\"1835\" data-end=\"1858\" data-col-size=\"md\"\u003ePutative consequence\u003c\/th\u003e\n\u003cth data-start=\"1858\" data-end=\"1883\" data-col-size=\"lg\"\u003eMechanistic rationale\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1898\" data-end=\"2715\"\u003e\n\u003ctr data-start=\"1898\" data-end=\"2094\"\u003e\n\u003ctd data-start=\"1898\" data-end=\"1935\" data-col-size=\"sm\"\u003eMood \/ antidepressant-like effects\u003c\/td\u003e\n\u003ctd data-start=\"1935\" data-end=\"1980\" data-col-size=\"md\"\u003efaster-acting behavioral effects in models\u003c\/td\u003e\n\u003ctd data-start=\"1980\" data-end=\"2094\" data-col-size=\"lg\"\u003eTREK-1 inhibition increases excitability\/plasticity in relevant circuits \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2095\" data-end=\"2293\"\u003e\n\u003ctd data-start=\"2095\" data-end=\"2110\" data-col-size=\"sm\"\u003eNeurogenesis\u003c\/td\u003e\n\u003ctd data-start=\"2110\" data-end=\"2157\" data-col-size=\"md\"\u003e↑ hippocampal neurogenesis signals in models\u003c\/td\u003e\n\u003ctd data-start=\"2157\" data-end=\"2293\" data-col-size=\"lg\"\u003eplasticity\/BDNF-linked pathways often rise downstream of excitability shifts (model dependent) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2294\" data-end=\"2509\"\u003e\n\u003ctd data-start=\"2294\" data-end=\"2323\" data-col-size=\"sm\"\u003eStroke \/ ischemia recovery\u003c\/td\u003e\n\u003ctd data-start=\"2323\" data-end=\"2383\" data-col-size=\"md\"\u003eimproved motor\/cognitive outcomes in rodent stroke models\u003c\/td\u003e\n\u003ctd data-start=\"2383\" data-end=\"2509\" data-col-size=\"lg\"\u003eexcitability + plasticity + potentially reduced apoptosis in injured tissue contexts \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2510\" data-end=\"2715\"\u003e\n\u003ctd data-start=\"2510\" data-end=\"2541\" data-col-size=\"sm\"\u003eβ-cell survival under stress\u003c\/td\u003e\n\u003ctd data-start=\"2541\" data-end=\"2593\" data-col-size=\"md\"\u003ereduced apoptotic β-cell death in ischemia models\u003c\/td\u003e\n\u003ctd data-start=\"2593\" data-end=\"2715\" data-col-size=\"lg\"\u003eTREK-1 is expressed beyond brain; protection signals reported in rodent contexts \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"2717\" data-end=\"2963\"\u003e\u003cstrong data-start=\"2717\" data-end=\"2757\"\u003eImportant interpretation constraint:\u003c\/strong\u003e Many of the “downstream” benefits are \u003cstrong data-start=\"2796\" data-end=\"2811\"\u003epreclinical\u003c\/strong\u003e outcomes; PE-22-28 is best thought of as a \u003cstrong data-start=\"2855\" data-end=\"2881\"\u003eresearch tool compound\u003c\/strong\u003e for TREK-1 biology and related phenotypes, not as a clinically validated therapy.\u003c\/p\u003e\n\u003chr data-start=\"2965\" data-end=\"2968\"\u003e\n\u003ch2 data-start=\"2970\" data-end=\"2999\"\u003e4) Chemistry and structure\u003c\/h2\u003e\n\u003cul data-start=\"3000\" data-end=\"3427\"\u003e\n\u003cli data-start=\"3000\" data-end=\"3067\"\u003e\n\u003cp data-start=\"3002\" data-end=\"3067\"\u003e\u003cstrong data-start=\"3002\" data-end=\"3015\"\u003eSequence:\u003c\/strong\u003e \u003cstrong data-start=\"3016\" data-end=\"3027\"\u003eGVSWGLR\u003c\/strong\u003e\u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3068\" data-end=\"3175\"\u003e\n\u003cp data-start=\"3070\" data-end=\"3175\"\u003e\u003cstrong data-start=\"3070\" data-end=\"3078\"\u003eCAS:\u003c\/strong\u003e commonly listed as \u003cstrong data-start=\"3098\" data-end=\"3114\"\u003e1801959-12-5\u003c\/strong\u003e in reagent catalogs. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3176\" data-end=\"3427\"\u003e\n\u003cp data-start=\"3178\" data-end=\"3427\"\u003e\u003cstrong data-start=\"3178\" data-end=\"3195\"\u003eDesign notes:\u003c\/strong\u003e Patents describe PE(22-28) as a \u003cstrong data-start=\"3228\" data-end=\"3244\"\u003ebase peptide\u003c\/strong\u003e used to design analogs (e.g., N-terminal modifications, substitutions, C-terminal derivatizations) to tune activity, stability, or labeling. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"3429\" data-end=\"3742\"\u003e\u003cstrong data-start=\"3429\" data-end=\"3466\"\u003eQuality-control note (practical):\u003c\/strong\u003e marketplace listings are not always consistent (some sites misreport the sequence). When writing professionally, it’s worth stating that \u003cstrong data-start=\"3604\" data-end=\"3637\"\u003eauthentic PE-22-28 is GVSWGLR\u003c\/strong\u003e, consistent with multiple reagent suppliers and patent language. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"3744\" data-end=\"3747\"\u003e\n\u003ch2 data-start=\"3749\" data-end=\"3799\"\u003e5) Pharmacokinetics and exposure considerations\u003c\/h2\u003e\n\u003cp data-start=\"3800\" data-end=\"3934\"\u003eThere is \u003cstrong data-start=\"3809\" data-end=\"3829\"\u003eno drug-label PK\u003c\/strong\u003e because PE-22-28 is not an approved medicine. As a \u003cstrong data-start=\"3881\" data-end=\"3897\"\u003e7-aa peptide\u003c\/strong\u003e, key PK realities typically include:\u003c\/p\u003e\n\u003cul data-start=\"3935\" data-end=\"4155\"\u003e\n\u003cli data-start=\"3935\" data-end=\"4004\"\u003e\n\u003cp data-start=\"3937\" data-end=\"4004\"\u003e\u003cstrong data-start=\"3937\" data-end=\"3958\"\u003erapid proteolysis\u003c\/strong\u003e in plasma\/tissues unless formulated\/modified,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4005\" data-end=\"4090\"\u003e\n\u003cp data-start=\"4007\" data-end=\"4090\"\u003e\u003cstrong data-start=\"4007\" data-end=\"4027\"\u003eroute dependence\u003c\/strong\u003e (systemic exposure and CNS exposure can differ substantially),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4091\" data-end=\"4155\"\u003e\n\u003cp data-start=\"4093\" data-end=\"4155\"\u003epossible \u003cstrong data-start=\"4102\" data-end=\"4121\"\u003eshort half-life\u003c\/strong\u003e without stabilization strategies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"4157\" data-end=\"4363\"\u003ePatents explicitly discuss chemical modifications\/analogs, which is often a sign that \u003cstrong data-start=\"4243\" data-end=\"4284\"\u003enative peptide stability and delivery\u003c\/strong\u003eare important development constraints. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"4365\" data-end=\"4368\"\u003e\n\u003ch2 data-start=\"4370\" data-end=\"4417\"\u003e6) Evidence base (what’s actually supported)\u003c\/h2\u003e\n\u003ch3 data-start=\"4419\" data-end=\"4460\"\u003e6.1 Strongest, most “anchored” claims\u003c\/h3\u003e\n\u003cul data-start=\"4461\" data-end=\"4832\"\u003e\n\u003cli data-start=\"4461\" data-end=\"4590\"\u003e\n\u003cp data-start=\"4463\" data-end=\"4590\"\u003e\u003cstrong data-start=\"4463\" data-end=\"4491\"\u003ePotent TREK-1 inhibition\u003c\/strong\u003e (IC₅₀ around 0.12 nM) and use as a pharmacological tool. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4591\" data-end=\"4832\"\u003e\n\u003cp data-start=\"4593\" data-end=\"4832\"\u003e\u003cstrong data-start=\"4593\" data-end=\"4617\"\u003ePreclinical outcomes\u003c\/strong\u003e reported in rodent models (stroke recovery, hippocampal neurogenesis; β-cell apoptosis reduction in ischemia contexts) in supplier summaries referencing underlying studies. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4834\" data-end=\"4867\"\u003e6.2 What is \u003cem data-start=\"4850\" data-end=\"4855\"\u003enot\u003c\/em\u003e established\u003c\/h3\u003e\n\u003cul data-start=\"4868\" data-end=\"5052\"\u003e\n\u003cli data-start=\"4868\" data-end=\"4984\"\u003e\n\u003cp data-start=\"4870\" data-end=\"4984\"\u003eRobust, replicated \u003cstrong data-start=\"4889\" data-end=\"4916\"\u003ehuman clinical efficacy\u003c\/strong\u003e for depression, cognition, stroke recovery, or metabolic endpoints.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4985\" data-end=\"5052\"\u003e\n\u003cp data-start=\"4987\" data-end=\"5052\"\u003eLong-term safety in humans at therapeutically relevant exposures.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5054\" data-end=\"5057\"\u003e\n\u003ch2 data-start=\"5059\" data-end=\"5108\"\u003e7) Safety and tolerability: scientific framing\u003c\/h2\u003e\n\u003cp data-start=\"5109\" data-end=\"5224\"\u003eBecause PE-22-28 is \u003cstrong data-start=\"5129\" data-end=\"5157\"\u003einvestigational\/research\u003c\/strong\u003e, safety is best discussed as \u003cem data-start=\"5187\" data-end=\"5223\"\u003emechanism-informed risk hypotheses\u003c\/em\u003e:\u003c\/p\u003e\n\u003cp data-start=\"5226\" data-end=\"5278\"\u003ePotential risks to consider in research translation:\u003c\/p\u003e\n\u003cul data-start=\"5279\" data-end=\"5852\"\u003e\n\u003cli data-start=\"5279\" data-end=\"5506\"\u003e\n\u003cp data-start=\"5281\" data-end=\"5506\"\u003e\u003cstrong data-start=\"5281\" data-end=\"5309\"\u003eCNS excitability shifts:\u003c\/strong\u003e TREK-1 inhibition can alter neuronal firing thresholds; depending on circuits, this can theoretically increase risk of adverse neuropsychiatric or sleep effects (speculative without human trials).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5507\" data-end=\"5661\"\u003e\n\u003cp data-start=\"5509\" data-end=\"5661\"\u003e\u003cstrong data-start=\"5509\" data-end=\"5535\"\u003eOff-tissue physiology:\u003c\/strong\u003e TREK-1 is expressed in multiple tissues; systemic dosing may have \u003cstrong data-start=\"5602\" data-end=\"5640\"\u003enon-CNS electrophysiologic effects\u003c\/strong\u003e (context dependent).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5662\" data-end=\"5852\"\u003e\n\u003cp data-start=\"5664\" data-end=\"5852\"\u003e\u003cstrong data-start=\"5664\" data-end=\"5694\"\u003eImmunogenicity\/impurities:\u003c\/strong\u003e small peptides are generally less immunogenic than proteins, but \u003cstrong data-start=\"5760\" data-end=\"5790\"\u003eimpurities and formulation\u003c\/strong\u003e can drive reactions—especially outside GMP medicine pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"5854\" data-end=\"5857\"\u003e\n\u003ch2 data-start=\"5859\" data-end=\"5909\"\u003e8) Regulatory status and real-world positioning\u003c\/h2\u003e\n\u003cp data-start=\"5910\" data-end=\"6055\"\u003ePE-22-28 is sold primarily as a \u003cstrong data-start=\"5942\" data-end=\"5962\"\u003eresearch reagent\u003c\/strong\u003e and is \u003cstrong data-start=\"5970\" data-end=\"5994\"\u003enot FDA\/EMA-approved\u003c\/strong\u003e for therapeutic use. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"6057\" data-end=\"6060\"\u003e\n\u003ch2 data-start=\"6062\" data-end=\"6129\"\u003e9) Future directions (what would make PE-22-28 “clinical-grade”)\u003c\/h2\u003e\n\u003col data-start=\"6130\" data-end=\"6662\"\u003e\n\u003cli data-start=\"6130\" data-end=\"6250\"\u003e\n\u003cp data-start=\"6133\" data-end=\"6250\"\u003e\u003cstrong data-start=\"6133\" data-end=\"6152\"\u003eValidated PK\/PD\u003c\/strong\u003e: demonstrate exposure and target engagement (TREK-1 occupancy\/functional biomarkers) in humans.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6251\" data-end=\"6425\"\u003e\n\u003cp data-start=\"6254\" data-end=\"6425\"\u003e\u003cstrong data-start=\"6254\" data-end=\"6288\"\u003eRoute\/formulation optimization\u003c\/strong\u003e: stabilizing analogs and delivery approaches (already implied by patent-driven analog design). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6426\" data-end=\"6662\"\u003e\n\u003cp data-start=\"6429\" data-end=\"6662\"\u003e\u003cstrong data-start=\"6429\" data-end=\"6466\"\u003eFunction-first clinical endpoints\u003c\/strong\u003e: if pursued for mood or recovery, trials should prioritize clinically meaningful outcomes (e.g., depressive symptom scales, functional recovery metrics) plus mechanistic neuroplasticity readouts.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003chr data-start=\"6664\" data-end=\"6667\"\u003e\n\u003ch2 data-start=\"6669\" data-end=\"6711\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"6712\" data-end=\"7160\"\u003e\n\u003cli data-start=\"6712\" data-end=\"6814\"\u003e\n\u003cp data-start=\"6714\" data-end=\"6814\"\u003eTREK-1 inhibition potency and preclinical effects summary: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6815\" data-end=\"6927\"\u003e\n\u003cp data-start=\"6817\" data-end=\"6927\"\u003eSequence\/identity and “smallest active spadin fragment” description: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6928\" data-end=\"7044\"\u003e\n\u003cp data-start=\"6930\" data-end=\"7044\"\u003ePatent text specifying \u003cstrong data-start=\"6953\" data-end=\"6964\"\u003eGVSWGLR\u003c\/strong\u003e and analog design built on PE(22-28): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7045\" data-end=\"7160\"\u003e\n\u003cp data-start=\"7047\" data-end=\"7160\"\u003eAdditional catalog confirmations (CAS\/identity; research tool framing)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684842369362,"sku":null,"price":40.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/PE-22-28_10mg.png?v=1770834803","url":"https:\/\/sciencepeptideslab.com\/products\/pe-22-28-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}